This is a working overview of AOD-9604, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-17. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Note that for Drug A, the % increase in unbound fraction is 100% – hence, Drug A's pharmacological effect can potentially double (depending on whether the free molecules get to their target before they are eliminated by metabolism or excretion). This change in pharmacologic effect could have adverse consequences. However, this effect is really only noticeable in closed systems where the pool of available proteins could potentially be exceeded by the number of drug molecules. Biological systems, such as humans and animals, are open systems where molecules can be gained, lost or redistributed and where the protein pool capacity is almost never exceeded by the number of drug molecules. A drug that is 99% bound means that 99% of the drug molecules are bound to blood proteins not that 99% of the blood proteins are bound with drug. When two, highly protein-bound drugs (A and B) are added into the same biological system it will lead to an initial small increase in the concentration of free drug A (as drug B ejects some of the drug A from its proteins). However, this free drug A is now more available for redistribution into the body tissues and/or for excretion. This means the total amount of drug in the system will decrease quite rapidly, keeping the free drug fraction (the concentration of free drug divided by the total drug concentration) constant and yielding almost no change in clinical effect.
The BOP was aware that the use of pentobarbital as their "new drug choice" would be challenged in the courts because some lawyers had said that "pentobarbital would flood prisoners' lungs with froth and foam, inflicting pain and terror akin to a death by drowning." BOP claimed that these concerns were unjustified and that their two expert witnesses asserted that the use of pentobarbital was "humane". On 25 July 2019, US Attorney General William Barr directed the federal government to resume capital punishment after 16 years, despite shortages of the compound caused by European Union restrictions and a lack of U.S. manufacturers. The federal protocol provides for intravenous administration of two syringes each containing 2.5 grams of pentobarbital sodium followed by a saline flush.
=== Part one === In 1897, in Idris, ten-year-old Lucie Herondale, daughter of Shadowhunter William "Will" Herondale, and half warlock/half Shadowhunter Theresa "Tessa" Gray, gets lost in the forest. She finds her way back with the help of a mysterious young boy. Six years later, in 1903, James Herondale and his friends, his parabatai Matthew Fairchild (son of Charlotte Fairchild), Thomas Lightwood, and Christopher Lightwood, defeat the first demon they have seen in a year. The demon recognizes James, who falls into the shadow realm (a unique power as a result of his warlock heritage) for the first time in 3 years. Meanwhile, Cordelia Carstairs enters the London society along with her brother Alastair and mother Sona. Her father has been arrested for supposedly mishandling a vampire raid, and the Carstairs wish to make powerful allies in London to save their reputation. The Carstairs are greeted by Tessa, James (Cordelia's childhood friend who she has a crush on), and Lucie (James' sister). Cordelia believes that her feelings for James might be requited. At the next day's ball, James requests Cordelia dance with him, but disappoints her when he suddenly leaves to greet Grace Blackthorn, the adopted ward of Tatiana Blackthorn. James met Grace in 1899, and has been in love with her since he was 13 years old. Lucie sees the mysterious boy from her childhood, who reveals himself to be the ghost of Jesse Blackthorn, the late son of Tatiana. His mother asked Downworlders to preserve his body, so his spirit has remained trapped in the in-between.
Sources: en.wikipedia.org
=== Enols and enolates === The α-carbon is important for enol- and enolate-based carbonyl chemistry as well. Chemical transformations affected by the conversion to either an enolate or an enol, in general, lead to the α-carbon acting as a nucleophile, becoming, for example, alkylated in the presence of primary haloalkane. An exception is in reaction with silyl chlorides, bromides, and iodides, where the oxygen acts as the nucleophile to produce silyl enol ether.
In 1973, he initiated a "Popular Revolution" with the formation of Basic People's Congresses, presented as a system of direct democracy, but retained personal control over major decisions. He outlined his Third International Theory that year in The Green Book. In 1977, Gaddafi transformed Libya into a new socialist state called a Jamahiriya ("state of the masses"). He officially adopted a symbolic role in governance but remained head of both the military and the Revolutionary Committees responsible for policing and suppressing dissent. During the 1970s and 1980s, Libya's unsuccessful border conflicts with Egypt and Chad, support for foreign militants and alleged responsibility for bombings of Pan Am Flight 103 and UTA Flight 772 left it increasingly isolated on the world stage. A particularly hostile relationship developed with Israel, the United States and the United Kingdom, resulting in the 1986 U.S. bombing of Libya and United Nations–imposed economic sanctions. From 1999, Gaddafi shunned pan-Arabism, and encouraged pan-Africanism and rapprochement with Western nations; he was Chairperson of the African Union from 2009 to 2010. Amid the 2011 Arab Spring, protests against widespread corruption and unemployment broke out in eastern Libya. The situation descended into civil war, in which NATO intervened militarily on the side of the anti-Gaddafist National Transitional Council (NTC). Gaddafi's government was overthrown; he retreated to Sirte only to be captured, tortured and killed by NTC militants.
== Awards and recognition == 1997: Newcomb Cleveland Prize 1998: W. Alden Spencer Award 1999: Albert Lasker Basic Medical Research Award 2000: Rosenstiel Award 2001: Gairdner Foundation International Award 2003: Louisa Gross Horwitz Prize 2003: Nobel Prize in Chemistry
Sources: en.wikipedia.org
== Theoretical, actual, and percent yields == The percent yield is a comparison between the actual yield—which is the weight of the intended product of a chemical reaction in a laboratory setting—and the theoretical yield—the measurement of pure intended isolated product, based on the chemical equation of a flawless chemical reaction, and is defined as,
=== Regier et al. (2005) === In a 2005 study of nuclear genomes Regier et al. suggest that Hexapoda is most closely related to Branchiopoda and Cephalocarida + Remipedia, thereby hexapods are "terrestrial crustaceans", thus supporting the Pancrustacea hypothesis that maxillopods are not monophyletic (in the following cladograms Maxillopoda subclasses are highlighted). In addition, there appeared some evidence against the Ostracoda monophyly: that Ostracoda subclass Podocopa may form a clade with Branchiura.
Uranium-233, bred from thorium-232 by neutron capture with intermediate decays steps omitted. Uranium-235, which occurs in natural uranium and enriched uranium Plutonium-239, bred from uranium-238 by neutron capture with intermediate decays steps omitted. Plutonium-241, bred from plutonium-240 directly by neutron capture. Fissile nuclides do not have a 100% chance of undergoing fission on absorption of a neutron. The chance is dependent on the nuclide as well as neutron energy. For low and medium-energy neutrons, the neutron capture cross sections for fission (σF), the cross section for neutron capture with emission of a gamma ray (σγ), and the percentage of non-fissions are in the table at right. Fertile nuclides in nuclear fuels include:
Plants grown under UVB light are more resistant to insect herbivory compared with plants grown under filters that exclude the radiation. When tomato plants are exposed to a pulse of UVB radiation and then weakly wounded, PIs accumulate throughout the plant. By themselves, neither the radiation nor weak wounding is sufficient to induce systemic PI accumulation. Tomato cell cultures respond similarly, with systemin and UVB acting together to activate MAPKs. Short pulses of UVB also cause alkalisation of the culturing medium.
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.